Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.

MLA

Sun, Roger, et al. “Radiomics to Predict Outcomes and Abscopal Response of Patients with Cancer Treated with Immunotherapy Combined with Radiotherapy Using a Validated Signature of CD8 Cells.” Journal for Immunotherapy of Cancer, vol. 8, no. 2, Nov. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-001429.

APA

Sun, R., Sundahl, N., Hecht, M., Putz, F., Lancia, A., Rouyar, A., Milic, M., Carré, A., Battistella, E., Alvarez Andres, E., Niyoteka, S., Romano, E., Louvel, G., Durand-Labrunie, J., Bockel, S., Bahleda, R., Robert, C., Boutros, C., Vakalopoulou, M., … Deutsch, E. (2020). Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001429

Chicago

Sun, Roger, Nora Sundahl, Markus Hecht, Florian Putz, Andrea Lancia, Angela Rouyar, Marina Milic, et al. 2020. “Radiomics to Predict Outcomes and Abscopal Response of Patients with Cancer Treated with Immunotherapy Combined with Radiotherapy Using a Validated Signature of CD8 Cells.” Journal for Immunotherapy of Cancer 8 (2). doi:10.1136/jitc-2020-001429.